FOGHORN THERAPEUTICS INC (FHTX) Fundamental Analysis & Valuation

NASDAQ:FHTX • US3441741077

4.805 USD
-0.12 (-2.34%)
Last: Mar 13, 2026, 03:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This FHTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to FHTX. FHTX was compared to 519 industry peers in the Biotechnology industry. Both the profitability and financial health of FHTX have multiple concerns. FHTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. FHTX Profitability Analysis

1.1 Basic Checks

  • FHTX had negative earnings in the past year.
  • FHTX had a negative operating cash flow in the past year.
  • In the past 5 years FHTX always reported negative net income.
  • In the past 5 years FHTX reported 4 times negative operating cash flow.
FHTX Yearly Net Income VS EBIT VS OCF VS FCFFHTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

  • FHTX's Return On Assets of -35.19% is fine compared to the rest of the industry. FHTX outperforms 61.85% of its industry peers.
Industry RankSector Rank
ROA -35.19%
ROE N/A
ROIC N/A
ROA(3y)-30.61%
ROA(5y)-27.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FHTX Yearly ROA, ROE, ROICFHTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

1.3 Margins

  • FHTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FHTX Yearly Profit, Operating, Gross MarginsFHTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. FHTX Health Analysis

2.1 Basic Checks

  • FHTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, FHTX has more shares outstanding
  • Compared to 5 years ago, FHTX has more shares outstanding
  • FHTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FHTX Yearly Shares OutstandingFHTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
FHTX Yearly Total Debt VS Total AssetsFHTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of -4.28, we must say that FHTX is in the distress zone and has some risk of bankruptcy.
  • FHTX has a Altman-Z score of -4.28. This is in the lower half of the industry: FHTX underperforms 60.12% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.28
ROIC/WACCN/A
WACC8.85%
FHTX Yearly LT Debt VS Equity VS FCFFHTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

  • A Current Ratio of 2.16 indicates that FHTX has no problem at all paying its short term obligations.
  • FHTX's Current ratio of 2.16 is on the low side compared to the rest of the industry. FHTX is outperformed by 75.34% of its industry peers.
  • A Quick Ratio of 2.16 indicates that FHTX has no problem at all paying its short term obligations.
  • FHTX's Quick ratio of 2.16 is on the low side compared to the rest of the industry. FHTX is outperformed by 73.22% of its industry peers.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 2.16
FHTX Yearly Current Assets VS Current LiabilitesFHTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. FHTX Growth Analysis

3.1 Past

  • FHTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.15%, which is quite impressive.
  • Looking at the last year, FHTX shows a decrease in Revenue. The Revenue has decreased by -3.91% in the last year.
  • FHTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 157.75% yearly.
EPS 1Y (TTM)41.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.35%
Revenue 1Y (TTM)-3.91%
Revenue growth 3Y157.75%
Revenue growth 5YN/A
Sales Q2Q%4.42%

3.2 Future

  • FHTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.17% yearly.
  • The Revenue is expected to grow by 14.65% on average over the next years. This is quite good.
EPS Next Y31.91%
EPS Next 2Y16.17%
EPS Next 3Y9.77%
EPS Next 5Y9.17%
Revenue Next Year1.63%
Revenue Next 2Y6.34%
Revenue Next 3Y9.24%
Revenue Next 5Y14.65%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
FHTX Yearly Revenue VS EstimatesFHTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
FHTX Yearly EPS VS EstimatesFHTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. FHTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FHTX. In the last year negative earnings were reported.
  • Also next year FHTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FHTX Price Earnings VS Forward Price EarningsFHTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FHTX Per share dataFHTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.17%
EPS Next 3Y9.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FHTX Dividend Analysis

5.1 Amount

  • FHTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FHTX Fundamentals: All Metrics, Ratios and Statistics

FOGHORN THERAPEUTICS INC

NASDAQ:FHTX (3/13/2026, 3:16:41 PM)

4.805

-0.12 (-2.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-12
Inst Owners71.71%
Inst Owner Change1.83%
Ins Owners7.55%
Ins Owner Change0%
Market Cap281.43M
Revenue(TTM)24.52M
Net Income(TTM)-72.12M
Analysts87.5
Price Target11.56 (140.58%)
Short Float %2.41%
Short Ratio6.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.9%
Min EPS beat(2)23.44%
Max EPS beat(2)26.37%
EPS beat(4)4
Avg EPS beat(4)18.49%
Min EPS beat(4)10.09%
Max EPS beat(4)26.37%
EPS beat(8)8
Avg EPS beat(8)21.63%
EPS beat(12)11
Avg EPS beat(12)18.92%
EPS beat(16)12
Avg EPS beat(16)9.32%
Revenue beat(2)2
Avg Revenue beat(2)21.5%
Min Revenue beat(2)14.02%
Max Revenue beat(2)28.98%
Revenue beat(4)3
Avg Revenue beat(4)-4.62%
Min Revenue beat(4)-61.83%
Max Revenue beat(4)28.98%
Revenue beat(8)6
Avg Revenue beat(8)1.01%
Revenue beat(12)8
Avg Revenue beat(12)18.87%
Revenue beat(16)9
Avg Revenue beat(16)26.35%
PT rev (1m)0%
PT rev (3m)-3.25%
EPS NQ rev (1m)2.37%
EPS NQ rev (3m)2.38%
EPS NY rev (1m)0.18%
EPS NY rev (3m)0.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-4.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.48
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-1.52
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS0.42
BVpS-1.53
TBVpS-1.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.19%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.61%
ROA(5y)-27.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.07%
Cap/Sales 2.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 2.16
Altman-Z -4.28
F-Score3
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)33.62%
Cap/Depr(5y)290.03%
Cap/Sales(3y)4.61%
Cap/Sales(5y)806.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.35%
EPS Next Y31.91%
EPS Next 2Y16.17%
EPS Next 3Y9.77%
EPS Next 5Y9.17%
Revenue 1Y (TTM)-3.91%
Revenue growth 3Y157.75%
Revenue growth 5YN/A
Sales Q2Q%4.42%
Revenue Next Year1.63%
Revenue Next 2Y6.34%
Revenue Next 3Y9.24%
Revenue Next 5Y14.65%
EBIT growth 1Y14.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.03%
EBIT Next 3Y5.72%
EBIT Next 5Y-5.7%
FCF growth 1Y26.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.07%
OCF growth 3YN/A
OCF growth 5YN/A

FOGHORN THERAPEUTICS INC / FHTX FAQ

Can you provide the ChartMill fundamental rating for FOGHORN THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to FHTX.


Can you provide the valuation status for FOGHORN THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to FOGHORN THERAPEUTICS INC (FHTX). This can be considered as Overvalued.


What is the profitability of FHTX stock?

FOGHORN THERAPEUTICS INC (FHTX) has a profitability rating of 1 / 10.


Can you provide the financial health for FHTX stock?

The financial health rating of FOGHORN THERAPEUTICS INC (FHTX) is 3 / 10.